Article
Biology
Gerit Theil, Carlotta Lindner, Joanna Bialek, Paolo Fornara
Summary: The detection and analysis of personalized predictive biomarkers through liquid biopsy offer a promising approach for personalized treatment and cancer progression monitoring in prostate cancer research. Further research on CTC phenotyping and their interactions with tumor-associated blood-released factors is essential for better personalized characterization.
Article
Oncology
Khrystany T. Isebia, Eshwari Dathathri, Noortje Verschoor, Afroditi Nanou, Anouk C. De Jong, Frank A. W. Coumans, Leon W. M. M. Terstappen, Jaco Kraan, John W. M. Martens, Ruchi Bansal, Martijn P. Lolkema
Summary: This study compared the composition of circulating tumor cells (CTCs) and tumor-derived extracellular vesicles (tdEVs) in the blood of patients with metastatic castration-naive prostate cancer (CNPC) and metastatic castration-resistant prostate cancer (CRPC). The study found potential differences between these biomarkers in the two disease stages, with lower CTC and tdEV levels in CNPC compared to CRPC patients. Furthermore, the study observed a decline in CTC/tdEV numbers 6 months after androgen deprivation therapy (ADT).
Article
Biochemistry & Molecular Biology
Levi Groen, Iris Kloots, David Englert, Kelly Seto, Lana Estafanos, Paul Smith, Gerald W. Verhaegh, Niven Mehra, Jack A. Schalken
Summary: The clinical utility of circulating tumor cells (CTC) as a non-invasive multipurpose biomarker is well recognized. The earliest methods for enriching CTCs relied on antibody-based positive selection, but it has limitations in capturing the heterogeneity of cancer. This study used the recently FDA-approved Parsortix (R) technology to enrich CTCs from prostate cancer patients and found that targeted CTC transcriptome profiling may be predictive of therapy response.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Multidisciplinary Sciences
Takeshi Ashizawa, Masayoshi Nagata, So Nakamura, Hisashi Hirano, Naoya Nagaya, Yan Lu, Shigeo Horie
Summary: In this study, the effectiveness of cabazitaxel in Japanese patients with metastatic castration-resistant prostate cancer (mCRPC) was evaluated. The results showed that the expression of AR-V7 was not associated with cabazitaxel sensitivity, and reductions in bone scan index (BSI) and prostate-specific antigen (PSA) during early stages of cabazitaxel treatment may predict overall survival (OS) in patients.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Rebeca Lozano, David Lorente, Isabel M. Aragon, Nuria Romero-Laorden, Paz Nombela, Joaquim Mateo, Alison H. M. Reid, Ylenia Cendon, Diletta Bianchini, Casilda Llacer, Shahneen K. Sandhu, Adam Sharp, Pasquale Rescigno, Teresa Garces, Maria I. Pacheco, Penelope Flohr, Christophe Massard, Pedro P. Lopez-Casas, Elena Castro, Johann S. de Bono, David Olmos
Summary: CTC enumeration and changes following treatment have shown superiority over PSA response in determining the outcome of mCRPC patients receiving AR signaling inhibitors but not taxanes. Early changes in CTCs were found to be better predictors of overall survival in mCRPC patients treated with docetaxel compared to PSA response endpoints.
Article
Urology & Nephrology
Liancheng Fan, Xiaochen Fei, Yinjie Zhu, Jiahua Pan, Jianjun Sha, Chenfei Chi, Yiming Gong, Xinxing Du, Lixin Zhou, Baijun Dong, Wei Xue
Summary: This study investigated the genomic profiles of Chinese patients with different stages of prostate cancer using germline and circulating tumor DNA sequencing. The results showed a similar frequency of deleterious germline alterations between patients with castration sensitive prostate cancer and metastatic castration resistant prostate cancer. Circulating tumor DNA sequencing may guide clinical treatment for metastatic prostate cancer.
JOURNAL OF UROLOGY
(2021)
Article
Oncology
Chun Wang, Zhenchao Zhang, Weelic Chong, Rui Luo, Ronald E. Myers, Jian Gu, Jianqing Lin, Qiang Wei, Bingshan Li, Timothy R. Rebbeck, Grace Lu-Yao, William K. Kelly, Hushan Yang
Summary: This study investigated the associations of CTCs and CTC-clusters with mCRPC prognosis using longitudinal samples, finding that CTC counts were associated with mCRPC outcomes, and the presence of CTC-clusters alone had prognostic value, improving CTC-based prognostic stratification. The findings suggest the potential of combining CTC and CTC-clusters as non-invasive means to monitor progression and predict survival in mCRPC.
Article
Oncology
Bram De Laere, Alessio Crippa, Ashkan Mortezavi, Christophe Ghysel, Prabhakar Rajan, Martin Eklund, Alexander Wyatt, Luc Dirix, Piet Ost, Henrik Gronberg, Johan Lindberg
Summary: Circulating tumour DNA profiling can efficiently accelerate biomarker discovery in oncology trials. In metastatic castration-resistant prostate cancer, the complex genomic landscape with rare driver gene alterations complicates biomarker identification, requiring large sample sizes for evaluation. Grouping genomic alterations within the same cellular pathways may provide increased precision for biomarker discovery, highlighting the importance of comprehensive genomic profiling for prognosis and treatment outcomes.
Article
Oncology
H. I. Scher, A. J. Armstrong, J. D. Schonhoft, A. Gill, J. L. Zhao, E. Barnett, E. Carbone, J. Lu, E. S. Antonarakis, J. Luo, S. Tagawa, C. H. dos Anjos, Q. Yang, D. George, R. Szmulewitz, D. C. Danila, R. Wenstrup, M. Gonen, S. Halabi
Summary: The study evaluated the prognostic significance of circulating tumor cell (CTC) number determined on the Epic Sciences platform in men with metastatic castration-resistant prostate cancer (mCRPC) treated with an androgen receptor signalling inhibitor (ARSI). The results showed a significant correlation between pre-treatment CTC number and overall survival (OS) in these patients, which was validated in an independent dataset. Additionally, a strong correlation was observed between CTC counts determined on the CellSearch and Epic platforms.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Biochemistry & Molecular Biology
Chaima Cherif, Dang Tan Nguyen, Clement Paris, Thi Khanh Le, Thibaud Sefiane, Nadine Carbuccia, Pascal Finetti, Max Chaffanet, Abdessamad El Kaoutari, Julien Vernerey, Ladan Fazli, Martin Gleave, Mohamed Manai, Philippe Barthelemy, Daniel Birnbaum, Francois Bertucci, David Taieb, Palma Rocchi
Summary: Menin (MEN1) protein is highly regulated by HSP27, overexpressed in high-grade PC and CRPC, and high MEN1 mRNA expression is associated with decreased biochemical relapse-free and overall survival. Silencing Menin helps inhibit CRPC cell proliferation, tumor growth, and restore chemotherapeutic sensitivity.
Article
Urology & Nephrology
Ethan S. Barnett, Nikolaus Schultz, Konrad H. Stopsack, Ernest T. Lam, Andrea Arfe, Jerry Lee, Jimmy L. Zhao, Joseph D. Schonhoft, Emily A. Carbone, Niamh M. Keegan, Andreas Wibmer, Yipeng Wang, David B. Solit, Wassim Abida, Richard Wenstrup, Howard I. Scher
Summary: Single-cell, shallow whole-genome sequencing (CTC sWGS) is a more effective method for detecting BRCA2 loss in patients with metastatic castration-resistant prostate cancer (mCRPC) compared to tissue biopsies.
Article
Oncology
Vicenc Ruiz de Porras, Albert Font, Alvaro Aytes
Summary: Taxanes are currently the most active chemotherapy drugs used in the treatment of mCRPC, but resistance easily develops, limiting long-term survival. Platinum-based treatments, in addition to taxanes, are the limited therapeutic options for patients progressing to taxanes. Therefore, further research on the role of platinum-based chemotherapy in mCRPC and the identification of predictive biomarkers are urgently needed.
Article
Oncology
Hui-Ming Lin, Nicole Yeung, Jordan F. Hastings, David R. Croucher, Kevin Huynh, Thomas G. Meikle, Natalie A. Mellett, Edmond M. Kwan, Ian D. Davis, Ben Tran, Kate L. Mahon, Alison Zhang, Martin R. Stockler, Karen Briscoe, Gavin Marx, Patricia Bastick, Megan L. Crumbaker, Anthony M. Joshua, Arun A. Azad, Peter J. Meikle, Lisa G. Horvath
Summary: The study found that in metastatic castration-resistant prostate cancer (mCRPC), blood lipids may be more informative than cytokines, with certain lipids consistently associated with poorer clinical outcomes and influencing immune response and treatment response. The correlation between circulating ceramides and cytokines suggests the regulation of immune responses by ceramides, and further research into metabolic interventions related to changes in lipid profiles is warranted.
Article
Oncology
Zainab A. H. Alebady, Mahsa Azizyan, Sirintra Nakjang, Emma Lishman-Walker, Dhuha Al-Kharaif, Scott Walker, Hui Xian Choo, Rebecca Garnham, Emma Scott, Katya L. L. Johnson, Craig N. N. Robson, Kelly Coffey
Summary: This study uncovers the genes and cellular pathways regulated by methyltransferase KMT5A in prostate cancer, providing insight into its oncogenic properties and potential therapeutic targeting. The key regulator CDC20 is shown to be controlled by KMT5A through histone methylation and p53 inhibition. Clinical samples further support the correlation between KMT5A and CDC20 expression, suggesting their importance as therapeutic targets for prostate cancer.
Review
Oncology
Dmitry Enikeev, Andrey Morozov, Diana Babaevskaya, Andrey Bazarkin, Bernard Malavaud
Summary: Liquid biopsy, which combines cell-dependent and cell-independent information from the blood stream, has the potential to revolutionize cancer management. However, the science behind liquid biopsies is not widely utilized. In this systematic review, the use of CTCs in prostate cancer management was summarized, highlighting their predictive value for disease progression, survival, and response to therapy.
